| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Nuclear Medicine, University Hospital, Free University of Brussels (AZ VUB), Brussels, Belgium
Correspondence: For correspondence or reprints contact: Patrick Flamen, MD, Department of Nuclear Medicine, University Hospital, AZ VUB Laarbeeklaan 101, B-1090 Brussels, Belgium.
ABSTRACT
Tetrofosmin is a new 99mTc-labeled myocardial perfusion imaging agent. Biodistribution studies suggest more favorable heart to-adjacent organ biokinetics than for 99mTc-sestamibi after injection during exercise. The aim of this work was to determine intra individually whether tetrofosmin is more suitable than sestamibi for pharmacological stress testing in a 1-day protocol. Methods: Thirty subjects underwent two similar 1-day, rest and dipyridamole stress imaging protocols: one using tetrofosmin, the other using sestamibi. SPECT was performed 60 min after tracer administration. Myocardial images were analyzed both visually and quantitatively. Results: Heart-to-liver activity ratios measured on the anterior SPECT projections were significantly higher for tetrofosmin than for sestamibi in the rest and stress studies. Heart-to-lung ratios were similar for both tracers. Significant linear correlations between tetrofosmin and sestamibi perfusion indices were found in normals and in patients with proven or suspected coronary artery disease. In segments showing abnormal uptake during stress, the perfusion indices were similar for tetrofosmin and sestamibi at rest and during stress. The degree of reversibility in these segments was also similar for both tracers. Finally, the extent, intensity and severity of perfusion defects were similar for both tracer studies. Conclusion: Tetrofosmin has a more optimal biodistribution than sestamibi when used in a 1-day, rest and dipyridamole stress myocardial SPECT imaging protocol. No significant difference in either the quality or diagnostic interpretation of the images could be demonstrated.
Key Words: technetium-99m-tetrofosmin • dipyridamole • technetium-99m-sestamibi • myocardial perfusion • single-photon emission computed tomography
This article has been cited by other articles:
|
|
 |
|
  S. Borges-Neto, R. H. Tuttle, L. K. Shaw, W. T. Smith IV, D. Jain, R. E. Coleman, and D. Whellan Outcome Prediction in Patients at High Risk for Coronary Artery Disease: Comparison between 99mTc Tetrofosmin and 99mTc Sestamibi Radiology, July 1, 2004; 232(1): 58 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Elhendy, R T van Domburg, F B Sozzi, D Poldermans, J J Bax, and J R T C Roelandt Impact of hypertension on the accuracy of exercise stress myocardial perfusion imaging for the diagnosis of coronary artery disease Heart, June 1, 2001; 85(6): 655 - 661. [Abstract] [Full Text]
|
|
|
|
 |
|
 I. Matsunari, F. Haas, N. T.B. Nguyen, G. Reidel, I. Wolf, R. Senekowitsch-Schmidtke, G. Stöcklin, and M. Schwaiger Comparison of Sestamibi, Tetrofosmin, and Q12 Retention in Porcine Myocardium J. Nucl. Med., May 1, 2001; 42(5): 818 - 823. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Soman, R. Taillefer, E. G. DePuey, J. E. Udelson, and A. Lahiri Enhanced detection of reversible perfusion defects by Tc-99m sestamibi compared to Tc-99m tetrofosmin during vasodilator stress SPECT imaging in mild-to-moderate coronary artery disease J. Am. Coll. Cardiol., February 1, 2001; 37(2): 458 - 462. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
